Collagen peptide supplementation for pain and function: is it effective?

Kviatkovsky, Shiloah A.; Hickner, Robert C.; Ormsbee, Michael J.

doi:10.1097/mco.0000000000000870

Cited by 12 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…The health benefits associated with the consumption of hydrolyzed collagen [22][23][24][25][26][27] as well as other animal-origin active substances such as whey [28][29][30][31] and royal jelly [32][33][34][35] promote them as ideal ingredients for immunomodulation purposes. Moreover, the antioxidant properties of Vaccinium myrtillus [36][37][38][39] and Echinacea purpurea [40][41][42][43], coupled with their anti-inflammatory and antimicrobial effects, sustain their use for promoting immunomodulation and homeostasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Acute Toxicity and Immunomodulation Assessment of a Novel Nutraceutical in Mice

Onisei¹,

Tihăuan

Dolete

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Achieving and maintaining a well-balanced immune system has righteously become an insightful task for the general population and an even more fundamental goal for those affected by immune-related diseases. Since our immune functions are indispensable in defending the body against pathogens, diseases and other external attacks, while playing a vital role in maintaining health and modulating the immune response, we require an on-point grasp of their shortcoming as a foundation for the development of functional foods and novel nutraceuticals. Seeing that immunoceuticals are considered effective in improving immune functions and reducing the incidence of immunological disorders, the main focus of this study was to assess the immunomodulatory properties and possible acute toxicity of a novel nutraceutical with active substances of natural origin on C57BL/6 mice for 21 days. We evaluated the potential hazards (microbial contamination and heavy metals) of the novel nutraceutical and addressed the acute toxicity according to OECD guidelines of a 2000 mg/kg dose on mice for 21 days. The immunomodulatory effect was assessed at three concentrations (50 mg/kg, 100 mg/kg and 200 mg/kg) by determining body and organ indexes through a leukocyte analysis; flow cytometry immunophenotyping of lymphocytes populations and their subpopulations (T lymphocytes (LyCD3+), cytotoxic suppressor T lymphocytes (CD3+CD8+), helper T lymphocytes (CD3+CD4+), B lymphocytes (CD3−CD19+) and NK cells (CD3−NK1.1.+); and the expression of the CD69 activation marker. The results obtained for the novel nutraceutical referred to as ImunoBoost indicated no acute toxicity, an increased number of lymphocytes and the stimulation of lymphocyte activation and proliferation, demonstrating its immunomodulatory effect. The safe human consumption dose was established at 30 mg/day.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

In Vivo Acute Toxicity and Immunomodulation Assessment of a Novel Nutraceutical in Mice

Onisei¹,

Tihăuan

Dolete

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Collagen supplementation has gained attention for its potential benefits in tissue repair and joint health 24 . Studies have shown positive effects on joint pain reduction and improved joint health with collagen hydrolysate supplementation 6,25 . However, there is limited research on the effects of collagen supplementation specifically on DOMS.…”

Section: Discussionmentioning

confidence: 99%

“…Various treatment strategies help alleviate the pain associated with DOMS, which can range from nutritional to physical therapeutic methods. A few of the treatment strategies include nonsteroidal anti-inflammatory drugs, massage, heat therapy, cold therapy, stretching, and transcutaneous electrical nerve stimulation (TENS) 3,4,6,7 .…”

Section: Introductionmentioning

confidence: 99%

A Pilot Study of the Effects of Collagen vs. Whey Protein Supplementation on Delayed Onset Muscle Soreness in Healthy Individuals

Rojas,

Mekhail,

Evans

et al. 2023

RDSP

View full text Add to dashboard Cite

Introduction: Delayed onset muscle soreness (DOMS) is a common condition characterized by muscle stiffness, pain, and inflammation following intense or unaccustomed exercise. Despite its prevalence, the underlying mechanisms of DOMS remain unclear. This study aimed to investigate the effects of collagen supplementation on tissue repair and pain associated with DOMS in exercise-trained individuals. Methods: Fourteen exercise-trained men (n=7) and women (n=7) were enrolled in a randomized, counterbalanced, crossover trial. Participants were assigned to either a whey protein group (n=8) or a collagen protein group (n=6). Each participant consumed 40g of their respective protein supplement daily for four consecutive days. Peak soreness was assessed using self-reported ratings and algometer measurements. Statistical analysis included independent samples t-tests and Levene's test for equality of variances. Results: The analysis revealed no significant difference in peak soreness between the whey protein and collagen protein groups at the 24-hour time point (t(12) = 1.33, p = 0.208). Both groups experienced a decrease in peak soreness over the 24-hour period, but the reduction was not statistically different between the groups. No significant differences were observed in other variables measured. Conclusions: These findings suggest that collagen protein supplementation did not significantly reduce peak soreness associated with DOMS compared to whey protein supplementation in exercise-trained individuals. While collagen supplementation has shown potential benefits in tissue repair and joint health, further research is needed to explore its specific effects on DOMS. Larger studies with different dosages and participant populations are warranted to obtain a more comprehensive understanding of collagen's impact on muscle soreness and tissue repair.

show abstract

“…НК-II, полученный из хряща куриной грудины, назначается при ОА коленного сустава [22]. Показано, что добавление коллагеновых пептидов способствует восстановлению соединительной ткани и уменьшает боль за счет увеличения выработки коллагена [23].…”

Section: терапевтическая эффективность коллагенаunclassified

Efficacy of undenatured and hydrolyzed type II collagen in the treatment of pain syndrome

Shavlovskaya¹,

Bokova²

2022

Russian Medical Inquiry

View full text Add to dashboard Cite

Collagens play an important structural role and contribute to the mechanical properties, organization and shape of tissues. In musculoskeletal system diseases (MSD), the amount of type II collagen in the cartilage extracellular matrix significantly decreases. Degradation and reduction of type II collagen are associated with osteoarthritis (OA). At present, SYSADOA (Symptomatic Slow Acting Drugs for Osteoarthritis) are widely used in the treatment of OA for oral and parenteral use. Besides, increased attention has been paid to the new treatment methods for OA based on a new promising type II collagen molecule: undenatured (UC-II) and hydrolyzed (HC-II) collagen. UC-II is a native collagen (fibrillar protein with a molecular weight of 300 kDa), whereas HC-II is a polypeptide (molecular weight of 2–9 kDa). The article describes the molecular mechanisms of action of UC-II and HC-II, and identifies the main differences between them. The diverse mechanism of action of the described collagen types determines their clinical use: UC-II is prescribed mainly in MSD, in particular OA, and HC-II is mainly used in cosmetology, as well as in MSD. The article also presents the study results demonstrating the safety and efficacy of drugs and dietary supplements containing UC-II and HC-II in relieving pain syndrome during OA. KEYWORDS: undenatured type II collagen native collagen, hydrolyzed collagen, collagen peptides, SYSADOA, pain syndrome, osteoarthritis. FOR CITATION: Shavlovskaya O.A., Bokova I.A., Romanov I.D., Shavlovsky N.I. Efficacy of undenatured and hydrolyzed type II collagen in the treatment of pain syndrome. Russian Medical Inquiry. 2022;6(10):571–575 (in Russ.). DOI: 10.32364/2587-6821-2022-6-10-571-575.

show abstract

Collagen peptide supplementation for pain and function: is it effective?

Cited by 12 publications

References 30 publications

In Vivo Acute Toxicity and Immunomodulation Assessment of a Novel Nutraceutical in Mice

In Vivo Acute Toxicity and Immunomodulation Assessment of a Novel Nutraceutical in Mice

A Pilot Study of the Effects of Collagen vs. Whey Protein Supplementation on Delayed Onset Muscle Soreness in Healthy Individuals

Efficacy of undenatured and hydrolyzed type II collagen in the treatment of pain syndrome

Contact Info

Product

Resources

About